

IN THE CLAIMS:

Please amend the claims and add new claims 54 to 63 as follows:

1. (Currently amended) A purified ~~polypeptide comprising~~ an antibody, or a functional fragment thereof, ~~that induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell,~~ wherein said antibody or functional fragment specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells ~~and not to non-neoplastic cells,~~ and comprises a sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least 85% identical to the amino acid sequence of SEQ ID NO:3.
2. (Currently amended) The ~~polypeptide~~ antibody or functional fragment of claim 1, wherein said ~~neoplastic cell is a colorectal adenocarcinoma, ovarian cancer, squamous cell lung carcinoma, or lobular mammary carcinoma cell~~ antibody or functional fragment inhibits cell proliferation of CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), or COLO-206F (DSMZ Accession No. ACC 21) cells.
3. (Cancelled)
4. (Currently amended) The purified ~~polypeptide~~ antibody or functional fragment of claim 1, wherein said ~~polypeptide inhibits cell proliferation~~ antibody or functional fragment induces apoptosis of a neoplastic cell to which it binds when bound to a neoplastic cell, but does not inhibit cell proliferation of a non-neoplastic cell at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.
5. (Cancelled).
6. (Cancelled).
7. (Currently amended) The purified ~~polypeptide~~ antibody or functional fragment of claim 1, wherein said ~~polypeptide~~ antibody or functional fragment comprises a sequence that is substantially at least 90% identical to the amino acid sequence of SEQ ID NO:1.

8. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said polypeptide antibody or functional fragment comprises a sequence that is substantially at least 90% identical to the amino acid sequence of SEQ ID NO:3.

9. (Currently amended) A purified ~~polypeptide comprising~~ an antibody, or functional fragment thereof, wherein said polypeptide antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:1.

10. (Currently amended) A purified ~~polypeptide comprising~~ an antibody, or functional fragment thereof, wherein said polypeptide antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:3.

11. (Currently amended) A purified ~~polypeptide comprising~~ an antibody, or functional fragment thereof, wherein said polypeptide antibody or functional fragment comprises the amino acid sequence of SEQ ID NOS:1 and 3.

12. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said antibody or functional fragment is a human antibody.

13. (Currently amended) The purified polypeptide antibody of claim 1, wherein said antibody is a monoclonal antibody.

14. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said ~~polypeptide is a functional fragment~~ that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells is selected from the group consisting of V_L , V_H , F_V , $[[F_C]]$ Fab, Fab', and $F(ab')_2$.

15. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said ~~polypeptide is a functional fragment~~ that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells ~~comprising~~ comprises a fragment that is substantially at least 90% identical to the sequence of SEQ ID NO:1 or SEQ ID NO:3.

16. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said ~~polypeptide is a functional fragment~~ that specifically binds to at least one

of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells comprising comprises a fragment of the sequence of SEQ ID NO: 1 or SEQ ID NQ:3.

17.-53. (Canceled)

54. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 90% identical to the amino acid sequence of SEQ ID NO:3.

55. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

56. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

57. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:1.

58. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:3.

59. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:1.

60. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:3.

61. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:1.

62. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:3.

63. (New) A purified antibody, or a functional fragment thereof that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, wherein the antibody comprises SEQ ID NO:1 and SEQ ID NO:3 with a conservative amino acid substitution in either SEQ ID NO:1 or SEQ ID NO:3.

64. (New) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:1.

65. (New) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:3.